. 2017 Jan 9;55(1):749–757. doi: 10.1080/13880209.2016.1275023

Table 2.

Effect of different doses of β-aescin administration on serum ALT, AST, ALP, total bilirubin and direct bilirubin after CCl₄ challenge. Values are expressed as mean ± SD.

Groups	ALT (IU/L)	AST (IU/L)	ALP (IU/L)	Total bilirubin (mg/dL)	Direct bilirubin (mg/dL)
Normal control	45.97 ± 8.76	44.19 ± 7.99	80.3 ± 16.21	0.21 ± 0.04	0.17 ± 0.04
CCl₄ control	206.7 ± 18.68^a	171.82 ± 12.19^a	259 ± 7.03^a	1.35 ± 0.08^a	1.05 ± 0.06^a
Silymarin 50 mg/kg treated	68.95 ± 9.27^a^,^b	64.68 ± 6.42^a^,^b	108.2 ± 4.83^a^,^b	0.42 ± 0.08^a^,^b	0.28 ± 0.04^a^,^b
β-Aescin 0.9 mg/kg treated	152.75 ± 13.53^a^,^b	128.3 ± 8.92^a^,^b	194.9 ± 9.81^a^,^b	0.97 ± 0.11^a^,^b	0.67 ± 0.02^a^,^b
β-Aescin 1.8 mg/kg treated	91.93 ± 9.57^a^,^b	83.2 ± 5.67^a^,^b	157.3 ± 9.39^a^,^b	0.60 ± 0.04^a^,^b	0.43 ± 0.03^a^,^b
β-Aescin 3.6 mg/kg treated	71.77 ± 9.91^a^,^b	71.39 ± 9.93^a^,^b	121.2 ± 5.94^a^,^b	0.40 ± 0.05^a^,^b	0.27 ± 0.04^a^,^b

p < 0.05 as compared with normal control.

p < 0.05 as compared with CCl₄ control.